Credit rating agency, ICRA has assigned BB+ rating to enhanced Rs 149.0 crore Fund based limits (enhanced from Rs 70.0 crore), Rs 197.1 crore Term loans (enhanced from Rs 144.6 crore) and $32 million term loans (enhanced from $25.5 million) of Hikal. The outlook on the long term rating is stable. The rating agency has also assigned A4+ rating to the enhanced Rs 105 crore (earlier Rs 125 crores) fund based limits and Rs 55 crore (enhanced from Rs. 45 crore) non fund based limits of the company.
Though a part of the long term loans of the company is denominated in foreign currency, ICRA’s ratings for the same are on national rating scale, as distinct from an international rating scale.
The rating derives strength from the company’s strong product profile, entrenched relationship with leading Pharma and Agro chemicals companies in the world and strong market position for Gabapentin business.
Hikal provides world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: